Cephalexin (monohydrate)

Cephalexin (Cefalexin) monohydrate is a potent, orally active new semisynthetic cephalosporin antibiotic with a broad antibacterial spectrum. Cephalexin (Cefalexin) monohydrate has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Cephalexin (Cefalexin) monohydrate targets penicillin-binding proteins (PBPs) to inhibit bacterial cell wall assembly. Cephalexin (Cefalexin) monohydrate is used for the research of pneumonia, strep throat, and bacterial endocarditis, et al^[1][2]. In Vitro: Cephalexin (Cefalexin) monohydrate (10 μg/mL) disrupts polymer peptidoglycan (PG) biogenesis by inactivating enzymes called penicillin-binding proteins (PBPs)^[1].
Cephalexin (Cefalexin) monohydrate inhibits a broad spectrum of grampositive and gram-negative organisms with MIC values of 2, 2, 2, 2, 4, 4.4 and 5.7 μg/mL for Bacillus anthracis, Edwardsiella taFda, Vibrio cholera, Pasteurella multocida, Edwardsiella tarda, Alcaligenes sp and Proteus rettgeri, respectively^[2]. In Vivo: Cephalexin (Cefalexin) monohydrate (0-50 mg/kg; p.o.; for 3.5 hours) has antibacterial activity in male Swiss-Webster mice with infected bacterial^[2].